Version history

{
  "session_id": "sess_8ec36980-febb-4093-a5a1-387ea5768480_task_66f1207e_recon",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"early PD proteogenomic hubs that are both causal enough and accessible enough to perturb as proximal driver in Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration\",\n      \"description\": \"early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable proximal phenotype before late disease pathology. The decisive test is multi-omics network centrality, druggability scoring, interactome validation, and SNCA iPSC-neuron perturbation assays.\",\n      \"target_gene\": \"SNCA\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.67,\n        \"therapeutic_potential\": 0.64,\n        \"mechanistic_plausibility\": 0.7,\n        \"druggability\": 0.54,\n        \"safety_profile\": 0.52,\n        \"competitive_landscape\": 0.58,\n        \"data_availability\": 0.66,\n        \"reproducibility\": 0.61\n      },\n      \"composite_score\": 0.626,\n      \"evidence_for\": [\n        {\n          \"claim\": \"Review identified convergent pathogenic mechanisms but highlighted that druggability assessment of network hubs in early PD remains an open challenge.\",\n          \"doi\": \"10.1038/s41583-024-00812-2\",\n          \"source\": \"Key genes and convergent pathogenic mechanisms in Parkinson disease\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"network hubs are often essential, pleiotropic, or inaccessible to safe pharmacologic modulation\",\n          \"doi\": \"10.1038/s41583-024-00812-2\",\n          \"source\": \"Key genes and convergent pathogenic mechanisms in Parkinson disease\"\n        }\n      ]\n    },\n    {\n      \"title\": \"Cell-state stratification is required to resolve Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration\",\n      \"description\": \"The question is likely underpowered or misleading unless analyses preserve the key strata: SNCA. Averaging across these strata could convert a causal subpopulation effect into a weak association.\",\n      \"target_gene\": \"\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.58,\n        \"novelty\": 0.64,\n        \"feasibility\": 0.73,\n        \"therapeutic_potential\": 0.55,\n        \"mechanistic_plausibility\": 0.65,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.62,\n        \"competitive_landscape\": 0.56,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.612,\n      \"evidence_for\": [\n        {\n          \"claim\": \"The open question explicitly depends on cell-type, region, or molecular-state resolution.\",\n          \"doi\": \"10.1038/s41583-024-00812-2\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"Stratified effects may reflect sampling or annotation artifacts rather than mechanism.\",\n          \"doi\": \"10.1038/s41583-024-00812-2\"\n        }\n      ]\n    },\n    {\n      \"title\": \"Perturbation-first validation should precede therapeutic claims for Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration\",\n      \"description\": \"The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.\",\n      \"target_gene\": \"\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.6,\n        \"feasibility\": 0.76,\n        \"therapeutic_potential\": 0.57,\n        \"mechanistic_plausibility\": 0.63,\n        \"druggability\": 0.48,\n        \"safety_profile\": 0.6,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.68,\n        \"reproducibility\": 0.66\n      },\n      \"composite_score\": 0.608,\n      \"evidence_for\": [\n        {\n          \"claim\": \"The proposed priority experiment is concrete: multi-omics network centrality, druggability scoring, interactome validation, and SNCA iPSC-neuron perturbation assays\",\n          \"doi\": \"10.1038/s41583-024-00812-2\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"Therapeutic tractability is not established by the current source evidence.\",\n          \"doi\": \"10.1038/s41583-024-00812-2\"\n        }\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"8ec36980-febb-4093-a5a1-387ea5768480\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"SNCA\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_reconstructs_evidence_for\"\n    }\n  ],\n  \"synthesis_summary\": \"Consensus: Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration is a valid debate target because it is anchored to Key genes and convergent pathogenic mechanisms in Parkinson disease and asks a falsifiable question about early PD proteogenomic hubs that are both causal enough and accessible enough to perturb. Dissent: the source evidence does not yet prove causality, and network hubs are often essential, pleiotropic, or inaccessible to safe pharmacologic modulation. The next step is multi-omics network centrality, druggability scoring, interactome validation, and SNCA iPSC-neuron perturbation assays.\"\n}",
  "tokens_used": "1284",
  "persona_id": "persona-synthesizer"
}